Long-term risks of increased use of intravenous iron

Lancet

Volumn 370, Issue 9586, 2007, Pages 481-482

  Sullivan, Jerome L ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON;

ANEMIA; ARTERY DISEASE; CHRONIC DISEASE; DRUG SAFETY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HUMAN; IRON STORAGE; LETTER; LONG TERM CARE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547687579     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61225-2     Document Type: Letter

References (5)

1. Auerbach M., Ballard H., and Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 369 (2007) 1502-1504
2. Strippoli G., Tognoni G., Navaneethan S., Nicolucci A., and Craig J. Haemoglobin targets: we were wrong, time to move on. Lancet 369 (2007) 346-350
3. Sullivan J. Is stored iron safe?. J Lab Clin Med 144 (2004) 280-284
4. Facchini F., and Saylor K. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52 (2003) 1204-1209
5. Zacharski L., Chow B., Howes P., et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 297 (2007) 603-610